Viral vector-mediated RNA interference

Current Opinion in Pharmacology

Volumn 10, Issue 5, 2010, Pages 534-542

  Couto, Linda B ^a   High, Katherine A ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; COPPER ZINC SUPEROXIDE DISMUTASE; HUNTINGTIN; INTERFERON; LENTIVIRUS VECTOR; MESSENGER RNA; MICRORNA; MICRORNA 26A; PARVOVIRUS VECTOR; PRION PROTEIN; RHODOPSIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

AMYOTROPHIC LATERAL SCLEROSIS; CYTOTOXICITY; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; INNATE IMMUNITY; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; RETINITIS PIGMENTOSA; REVIEW; RNA INTERFERENCE; SPINOCEREBELLAR DEGENERATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; GENE THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; MICRORNAS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 77956650867     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.06.007     Document Type: Review

References (52)

1. Zamore P.D., Haley B. Ribo-gnome: the big world of small RNAs. Science 2005, 309:1519-1524.
2. Hannon G.J. RNA interference. Nature 2002, 418:244-251.
3. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
4. Meister G., Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004, 431:343-349.
5. Kim Y.K., Kim V.N. Processing of intronic microRNAs. EMBO J 2007, 26:775-783.
6. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
7. Krutzfeldt J., Stoffel M. MicroRNAs: a new class of regulatory genes affecting metabolism 3. Cell Metab 2006, 4:9-12.
8. Zhang C. Novel functions for small RNA molecules 1. Curr Opin Mol Ther 2009, 11:641-651.
9. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
10. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007, 6:443-453.
11. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
12. Paddison P.J., Caudy A.A., Bernstein E., Hannon G.J., Conklin D.S. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002, 16:948-958.
13. Yi R., Qin Y., Macara I.G., Cullen B.R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003, 17:3011-3016.
14. Xia H., Mao Q., Eliason S.L., Harper S.Q., Martins I.H., Orr H.T., Paulson H.L., Yang L., Kotin R.M., Davidson B.L. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004, 10:816-820.
15. Boudreau R.L., McBride J.L., Martins I., Shen S., Xing Y., Carter B.J., Davidson B.L. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 2009, 17:1053-1063.
16. McBride J.L., Boudreau R.L., Harper S.Q., Staber P.D., Monteys A.M., Martins I., Gilmore B.L., Burstein H., Peluso R.W., Polisky B., et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A 2008, 105:5868-5873.
17. Harper S.Q., Staber P.D., He X., Eliason S.L., Martins I.H., Mao Q., Yang L., Kotin R.M., Paulson H.L., Davidson B.L. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A 2005, 102:5820-5825.
18. Rodriguez-Lebron E., ovan-Wright E.M., Nash K., Lewin A.S., Mandel R.J. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther 2005, 12:618-633.
19. White M.D., Farmer M., Mirabile I., Brandner S., Collinge J., Mallucci G.R. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci U S A 2008, 105:10238-10243.
20. Towne C., Aebischer P. Lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi. Methods Mol Biol 2009, 555:87-108.
21. O'Reilly M., Palfi A., Chadderton N., Millington-Ward S., Ader M., Cronin T., Tuohy T., Auricchio A., Hildinger M., Tivnan A., et al. RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am J Hum Genet 2007, 81:127-135.
22. Palfi A., Millington-Ward S., Chadderton N., O'Reilly M., Goldmann T., Humphries M.M., Li T., Wolfrum U., Humphries P., Kenna P.F., Farrar G.J. Adeno-associated virus-mediated rhodopsin replacement provides therapeutic benefit in mice with a targeted disruption of the rhodopsin gene. Hum Gene Ther 2010, 21:311-323.
23. Grimm D., Streetz K.L., Jopling C.L., Storm T.A., Pandey K., Davis C.R., Marion P., Salazar F., Kay M.A. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006, 441:537-541.
24. Li M.J., Kim J., Li S., Zaia J., Yee J.K., Anderson J., Akkina R., Rossi J.J. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005, 12:900-909.
25. Anderson J., Li M.J., Palmer B., Remling L., Li S., Yam P., Yee J.K., Rossi J., Zaia J., Akkina R. Safety and efficacy of a lentiviral vector containing three anti-HIV genes - CCR5 ribozyme, tat-rev siRNA, and TAR decoy - in SCID-hu mouse-derived T cells. Mol Ther 2007, 15:1182-1188.
26. Fechner H., Sipo I., Westermann D., Pinkert S., Wang X., Suckau L., Kurreck J., Zeichhardt H., Muller O., Vetter R., et al. Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. J Mol Med 2008, 86:987-997.
27. Hacke K., Falahati R., Flebbe-Rehwaldt L., Kasahara N., Gaensler K.M. Suppression of HLA expression by lentivirus-mediated gene transfer of siRNA cassettes and in vivo chemoselection to enhance hematopoietic stem cell transplantation. Immunol Res 2009, 44:112-126.
28. Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005, 23:457-462.
29. Hornung V., Guenthner-Biller M., Bourquin C., Ablasser A., Schlee M., Uematsu S., Noronha A., Manoharan M., Akira S., de Fougerolles A., et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005, 11:263-270.
30. Bridge A.J., Pebernard S., Ducraux A., Nicoulaz A.L., Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003, 34:263-264.
31. Pebernard S., Iggo R.D. Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 2004, 72:103-111.
32. Fish R.J., Kruithof E.K. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol Biol 2004, 5:9-15.
33. Kenworthy R., Lambert D., Yang F., Wang N., Chen Z., Zhu H., Zhu F., Liu C., Li K., Tang H. Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation. Nucleic Acids Res 2009, 37:6587-6599.
34. Robbins M.A., Li M., Leung I., Li H., Boyer D.V., Song Y., Behlke M.A., Rossi J.J. Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol 2006, 24:566-571.
35. An D.S., Qin F.X., Auyeung V.C., Mao S.H., Kung S.K., Baltimore D., Chen I.S. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther 2006, 14:494-504.
36. Chen C.C., Ko T.M., Ma H.I., Wu H.L., Xiao X., Li J., Chang C.M., Wu P.Y., Chen C.H., Han J.M., et al. Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. Gene Ther 2007, 14:11-19.
37. Jackson A.L., Bartz S.R., Schelter J., Kobayashi S.V., Burchard J., Mao M., Li B., Cavet G., Linsley P.S. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003, 21:635-637.
38. Denovan-Wright E.M., Rodriguez-Lebron E., Lewin A.S., Mandel R.J. Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo. Neurobiol Dis 2008, 29:446-455.
39. Yi R., Doehle B.P., Qin Y., Macara I.G., Cullen B.R. Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs 1. RNA 2005, 11:220-226.
40. Boudreau R.L., Martins I., Davidson B.L. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 2009, 17:169-175.
41. Castanotto D., Sakurai K., Lingeman R., Li H., Shively L., Aagaard L., Soifer H., Gatignol A., Riggs A., Rossi J.J. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res 2007, 35:5154-5164.
42. An D.S., Donahue R.E., Kamata M., Poon B., Metzger M., Mao S.H., Bonifacino A., Krouse A.E., Darlix J.L., Baltimore D., et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci U S A 2007, 104:13110-13115.
43. Giering J.C., Grimm D., Storm T.A., Kay M.A. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 2008, 16:1630-1636.
44. Zeng Y., Wagner E.J., Cullen B.R. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 2002, 9:1327-1333.
45. Zeng Y., Cai X., Cullen B.R. Use of RNA polymerase II to transcribe artificial microRNAs. Methods Enzymol 2005, 392:371-380.
46. Boudreau R.L., Monteys A.M., Davidson B.L. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 2008, 14:1834-1844.
47. Cai X., Hagedorn C.H., Cullen B.R. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004, 10:1957-1966.
48. Aagaard L.A., Zhang J., von Eije K.J., Li H., Saetrom P., Amarzguioui M., Rossi J.J. Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther 2008, 15:1536-1549.
49. Liu Y.P., Haasnoot J., ter Brake O., Berkhout B., Konstantinova P. Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res 2008, 36:2811-2824.
50. Gaur A., Jewell D.A., Liang Y., Ridzon D., Moore J.H., Chen C., Ambros V.R., Israel M.A. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines 1. Cancer Res 2007, 67:2456-2468.
51. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., Chang T.C., Vivekanandan P., Torbenson M., Clark K.R., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
52. Matzke M.A., Birchler J.A. RNAi-mediated pathways in the nucleus. Nat Rev Genet 2005, 6:24-35.